OncologyTube Professional - Patients Click Here
InternationalMyelomaFoundation
100,800 video views
InternationalMyelomaFoundation: Videos
03:27
In this week’s video, Dr. Brian G.M. Durie talks about ways myeloma patients, caregivers, or family members can give back to the myeloma community. The BOTTOM LINE: The Myeloma Warrior Spirit means having the energy and resilience to seek out the best care for patients.
02:30
In this week’s video, Dr. Brian G.M. Durie explains the results of the A.R.R.O.W. trial, which proved the efficacy and safety of once-a-week dosing of Kyprolis for myeloma patients. BOTTOM LINE: The FDA approval of once-weekly dosing of Kyprolis is effective, more convenient for patients, and d...
03:41
In this week’s video, Dr. Brian G.M. Durie discusses the Black Swan Research Initiative’s 3 “Cure” trials, which use new treatment protocols. The BOTTOM LINE: Using new treatment protocols with MRD-negativity and negative PET/CT scans as endpoints, there is a strong possibility that we will...
04:07
In this week’s video, Dr. Brian G.M. Durie details the results of the STORM 2b trial, which uses selinexor in combination with dexamethasone to treat multiple myeloma patients who are refractory to IMiDs, proteasome inhibitors, and daratumumab. BOTTOM LINE: Selinexor will likely be approved by the FDA, demonstrating its safety and efficacy in co...
03:31
In this week’s video, Dr. Durie discusses the two main types of minimal residual disease (MRD) tests for multiple myeloma – next-generation sequencing (NGS) and next-generation flow (NGF). The BOTTOM LINE: The FDA approval of the NGS test for MRD is excellent news, but this testing is still not r...
03:02
In this week’s video, Dr. Brian G.M. Durie comments on why it is not necessary for multiple myeloma patients to have their DNA sequenced. BOTTOM LINE: For myeloma patients, DNA sequencing is helpful in research trials, but it is not necessary for the day-to-day management of the disease.
04:00
In this video, Dr. Brian G.M. Durie explains how researchers are studying minimal residual disease (MRD) testing further to better understand sustained MRD-negativity. The BOTTOM LINE: MRD-negative status is great for a myeloma patient to have, but it still does not mean the patient is cured.
04:03
In this video, Dr. Brian G.M. Durie explains that active myeloma is diagnosed if a patient has CRAB features and myeloma-definin​g events. He also sheds light on a new set of criteria for high-risk smoldering multiple myeloma, known as the 2/20/20 rule. BOTTOM LINE: Talk with your doctor to asses...
02:25
In this week’s video, Dr. Brian G.M. Durie explains how the ARROW study demonstrated efficacy and low toxicity for weekly dosing of carfilzomib. BOTTOM LINE: Ensure your doctor is aware of the ARROW study in order to consider once-weekly dosing of carfilzomib.
03:46
In this video, Dr. Brian G.M. Durie explains how high-dose melphalan therapy that precedes an ASCT may cause some side effects and how an ASCT itself may result in some low-risk complications. The BOTTOM LINE: Autologous stem cell transplant is still a recommended therapy, if feasible, and it is ...
dsfsd